Effect of perampanel in reducing depression in patients with focal epilepsy

IF 2 Q3 NEUROSCIENCES

IBRO Neuroscience Reports Pub Date : 2025-01-15 DOI:10.1016/j.ibneur.2025.01.007

Min Ming , Long Chen , Jian Huang , Ying Huang , Jiali Yin

{"title":"Effect of perampanel in reducing depression in patients with focal epilepsy","authors":"Min Ming , Long Chen , Jian Huang , Ying Huang , Jiali Yin","doi":"10.1016/j.ibneur.2025.01.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>High prevalence of depression is very common in epilepsy. This study aimed to discover the effect of perampanel on depression in patients with focal epilepsy.</div></div><div><h3>Methods</h3><div>This is a prospective observational study. We included a total of 68 patients with focal EP, which were treated with perampanel. We analyzed data before perampanel treatment and at 6 and 12 months of follow-up of the optimal dose. Using the Beck Depression Inventory-II (BDI-II) scale to evaluate depression, the Mini-Mental State Examination (MMSE) to assess the cognitive function, and the Quality of Life in Epilepsy-31 items (QOLIE-31) to estimate the quality of life of EP patients.</div></div><div><h3>Results</h3><div>The BDI-II score improved significantly compared to before treatment and at 6 and 12 months of follow-up (P < 0.001). The mean total QOLIE-31 score significantly increased from 82.9 ± 20.4 to 88.7 ± 21.2 at the 12-month follow-up (P < 0.001). In addition, seizure control was improved significantly at 12 months: 32.1 % of patients were seizure-free, and 73.2 % were responsive. Moreover, there was statistical relationship between improvement in depression and seizure control. The MMSE score was not different before and after treatment (P > 0.05). Multiple Regression Analysis was found that annual family income, etiology, the frequency of attacks in recent years, types of ASMs and the age were the influence factors of pirampanel in reducing depression (<em>P</em>＜0.05).</div></div><div><h3>Conclusion</h3><div>Perampanel reduced depression symptoms in patients with focal epilepsy, although the lack of a control group or the relatively small sample size.</div></div>","PeriodicalId":13195,"journal":{"name":"IBRO Neuroscience Reports","volume":"18 ","pages":"Pages 257-262"},"PeriodicalIF":2.0000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IBRO Neuroscience Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667242125000077","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

High prevalence of depression is very common in epilepsy. This study aimed to discover the effect of perampanel on depression in patients with focal epilepsy.

Methods

This is a prospective observational study. We included a total of 68 patients with focal EP, which were treated with perampanel. We analyzed data before perampanel treatment and at 6 and 12 months of follow-up of the optimal dose. Using the Beck Depression Inventory-II (BDI-II) scale to evaluate depression, the Mini-Mental State Examination (MMSE) to assess the cognitive function, and the Quality of Life in Epilepsy-31 items (QOLIE-31) to estimate the quality of life of EP patients.

Results

The BDI-II score improved significantly compared to before treatment and at 6 and 12 months of follow-up (P < 0.001). The mean total QOLIE-31 score significantly increased from 82.9 ± 20.4 to 88.7 ± 21.2 at the 12-month follow-up (P < 0.001). In addition, seizure control was improved significantly at 12 months: 32.1 % of patients were seizure-free, and 73.2 % were responsive. Moreover, there was statistical relationship between improvement in depression and seizure control. The MMSE score was not different before and after treatment (P > 0.05). Multiple Regression Analysis was found that annual family income, etiology, the frequency of attacks in recent years, types of ASMs and the age were the influence factors of pirampanel in reducing depression (P＜0.05).

Conclusion

Perampanel reduced depression symptoms in patients with focal epilepsy, although the lack of a control group or the relatively small sample size.

查看原文本刊更多论文

perampanel减轻局灶性癫痫患者抑郁的作用

背景：抑郁症在癫痫患者中非常普遍。本研究旨在探讨perampanel对局灶性癫痫患者抑郁的影响。方法前瞻性观察性研究。我们共纳入68例局灶性EP患者，这些患者接受perampanel治疗。我们分析了perampanel治疗前以及最佳剂量6个月和12个月随访时的数据。采用贝克抑郁量表- ii （BDI-II）评估抑郁，采用迷你精神状态检查（MMSE）评估认知功能，采用癫痫生活质量-31项目（QOLIE-31）评估EP患者的生活质量。结果BDI-II评分较治疗前及随访6、12个月有显著改善（P <； 0.001）。12个月随访时，QOLIE-31平均总分由82.9 ± 20.4分显著提高至88.7 ± 21.2分（P <； 0.001）。此外，12个月时癫痫发作控制显著改善：32.1% %的患者无癫痫发作，73.2% %的患者有反应。此外，抑郁症的改善与癫痫发作的控制之间也存在统计学上的关系。治疗前后MMSE评分差异无统计学意义（P >； 0.05）。多元回归分析发现，家庭年收入、病因、近年来发作次数、asm类型、年龄是影响吡兰板减轻抑郁的因素（P<0.05）。结论perampanel可减轻局灶性癫痫患者的抑郁症状，但缺乏对照组或样本量相对较小。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊